Startups
Premas is developing transformational technologies and partnering with pharmaceutical companies around the world to expedite their drug discovery programs by cutting down significantly both on costs & time to clinics.
Axtex-4D, a three-dimensional cell culture platform, engineered to produce high-throughput screens for targeted immuno-oncology drug candidates, is compelling scientists to relook at their tumor-targeting strategies. The ex-vivo culture systematically mirrors the in-vivo tumor microenvironment and is poised to revolutionize both drug discovery & combinatorial therapies.
D-Crypt, a platform for 'difficult-to-express’ proteins, is designed to considerably reduce time, cost, and risks associated with producing high-quality recombinant proteins. D-Crypt combines a yeast expression host with over 20 custom-made expression vectors.
C-Qwence, our naive India-based Antibody Library is harnessing the power of a genetic pool that is more diverse than any other region and has exposures to infectious diseases and changes in an environment not seen in Europe or America. C-Qwence captures a wealth of novel genetics and protective immune responses, demonstrated in the unique profiles of individual antibodies isolated from the libraries.
Combining our breakthrough technologies with state-of-the-art Gene to IND biologics development capabilities, Premas is seeking new partnerships with pharmaceutical companies to help accelerate the delivery of new medicines to patients.
Axtex-4D, a three-dimensional cell culture platform, engineered to produce high-throughput screens for targeted immuno-oncology drug candidates, is compelling scientists to relook at their tumor-targeting strategies. The ex-vivo culture systematically mirrors the in-vivo tumor microenvironment and is poised to revolutionize both drug discovery & combinatorial therapies.
D-Crypt, a platform for 'difficult-to-express’ proteins, is designed to considerably reduce time, cost, and risks associated with producing high-quality recombinant proteins. D-Crypt combines a yeast expression host with over 20 custom-made expression vectors.
C-Qwence, our naive India-based Antibody Library is harnessing the power of a genetic pool that is more diverse than any other region and has exposures to infectious diseases and changes in an environment not seen in Europe or America. C-Qwence captures a wealth of novel genetics and protective immune responses, demonstrated in the unique profiles of individual antibodies isolated from the libraries.
Combining our breakthrough technologies with state-of-the-art Gene to IND biologics development capabilities, Premas is seeking new partnerships with pharmaceutical companies to help accelerate the delivery of new medicines to patients.
Overview
Location
India, Haryana, Gurugram
Employees
51-200
Founded date
2005
Mentions in press and media 2
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Mar 19, 2021 | Premas Biotech and Oramed Announce Oral COVID-19 Vaccine Candidate That Produces Antibodies After a Single Dose | GURUGRAM, India--(BUSINESS WIRE)--Mar 19, 2021-- Premas Biotech, a developer of novel biotherapeutic and vaccine candidates, announced today the development of an oral COVID-19 vaccine that has shown efficacy after a single dose, in conjunc... |
Reviews 0
FAQ about Premas Biotech
When was Premas Biotech founded?
Premas Biotech was founded in 2005.
What has the press written about Premas Biotech?
Parsers VC has collected 2 articles mentioning Premas Biotech, among them “Premas Biotech and Oramed Announce Oral COVID-19 Vaccine Candidate That Produces Antibodies After a Single Dose” (Mar 19, 2021).
Is Premas Biotech still active?
Yes, Premas Biotech is active; its latest activity on Parsers VC dates from Apr 4, 2023.